clinical trial

Chip Petricoin, Mariaelena Pierobon, Alex Reeder with Side-Out poster

The Side-Out Protocol: A Scientist’s Perspective

As a physician-scientist, I have been part of the Side-Out trial since 2009. The major goal of the trial is the improvement of survival rates of metastatic breast cancer patients through the delivery of what is known as “precision medicine.” But what does the term really mean? I have spent hundreds of hours at the

The Side-Out Protocol: A Scientist’s Perspective Read More »

Side-Out Foundation Awards $160K to the FNIH

Rick Dunetz presents the check to FNIH (from left to right: David Wholley (director, The Biomarkers Consortium, FNIH), Dr. Scott Campbell (executive director and CEO, FNIH), Rick Dunetz (founder and executive director, Side-Out), Dr. Emanuel (Chip) Petricoin (co-director, GMU Center for Applied Proteomics and Molecular Medicine) and Bryant Dunetz (Rick’s dad and COO, Side-Out)) From

Side-Out Foundation Awards $160K to the FNIH Read More »

Side-Out Protocol: Year One

Fairfax, VA — March 29, 2011 — The Side-Out Foundation is funding a study looking at a novel approach in treating patients living with advanced breast cancer. This clinical trial (SO-BCA-001) is laying the groundwork for biologically based treatments for breast cancer, utilizing molecular profiling of the patient’s tumor tissue to find potential targets and

Side-Out Protocol: Year One Read More »